RNA Interference Therapies Are Enjoying a Renaissance
Gene silencing is firmly back on the R&D radar screen in the fight to combat intractable disease after a hiatus of several years. Promising results from early clinical results have begun to attract investors into the space again with well over $200 million poured into this sector so far in 2013; and public companies developing RNA-based drugs have seen their share prices soar.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter